Viking Therapeutics announces proposed public offering of $350 million of shares of its common stock (85.05 +46.57)
Viking currently intends to use the net proceeds from the proposed offering for continued development of its VK2809, VK2735 and VK0214 programs and for general research and development, working capital and general corporate purposes.